Assessment of fibrotic burden among chronic hepatitis B virus-infected patients with normal transaminase level
暂无分享,去创建一个
[1] Hongbing Shen,et al. Hepatitis B virus infection and risk of non‐alcoholic fatty liver disease: A population‐based cohort study , 2018, Liver international : official journal of the International Association for the Study of the Liver.
[2] Casado Marta,et al. Characterization and evaluation of liver fibrosis grade in patients with chronic hepatitis B virus infection and normal transaminases , 2018, Clinical and molecular hepatology.
[3] B. McMahon,et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance , 2018, Hepatology.
[4] H. Lee,et al. High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B , 2017, Gut.
[5] Vincent Wai-Sun Wong,et al. New trends on obesity and NAFLD in Asia. , 2017, Journal of hepatology.
[6] Thomas Berg,et al. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. , 2017, Journal of hepatology.
[7] Marcello Maida,et al. The severity of steatosis influences liver stiffness measurement in patients with nonalcoholic fatty liver disease , 2015, Hepatology.
[8] V. Wong,et al. Hepatitis B virus infection and fatty liver in the general population. , 2012, Journal of hepatology.
[9] Y. N. Park,et al. Risk assessment of hepatitis B virus–related hepatocellular carcinoma development using liver stiffness measurement (FibroScan) , 2011, Hepatology.
[10] 최은희,et al. Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using liver stiffness measurement (FibroScan). , 2011 .
[11] V. Wong,et al. Metabolic syndrome increases the risk of liver cirrhosis in chronic hepatitis B , 2008, Gut.
[12] Eva Herrmann,et al. Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. , 2008, Gastroenterology.
[13] Patrice Cacoub,et al. Meta-analyses of FibroTest diagnostic value in chronic liver disease , 2007, BMC gastroenterology.
[14] P. Loehrer,et al. Risk of Hepatocellular Carcinoma Across a Biological Gradient of Serum Hepatitis B Virus DNA Level , 2007 .
[15] Guan-Tarn Huang,et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. , 2006, JAMA.
[16] R. Fisher,et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values , 2003, Hepatology.
[17] M. Brunetto,et al. Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study. , 2002, Journal of hepatology.